Balakrishnan Pachamuthu, Kumarasamy Nagalingeswaran, Kantor Rami, Solomon Suniti, Vidya Sundararajan, Mayer Kenneth H, Newstein Michael, Thyagarajan Sadras P, Katzenstein David, Ramratnam Bharat
YRG CARE, Centre for AIDS Research and Education, VHS, Taramani, Chennai 600 113, India.
AIDS Res Hum Retroviruses. 2005 Apr;21(4):301-5. doi: 10.1089/aid.2005.21.301.
Most studies of HIV-1 drug resistance have examined subtype B viruses; fewer data are available from developing countries, where non-B subtypes predominate. We determined the prevalence of mutations at protease and reverse transcriptase drug resistance positions in antiretroviral drug-naive individuals in southern India. The pol region of the genome was amplified from plasma HIV-1 RNA in 50 patients. All sequences clustered with HIV-1 subtype C. All patients had at least one protease and/or RT mutation at a known subtype B drug resistance position. Twenty percent of patients had mutations at major protease inhibitor resistance positions and 100% had mutations at minor protease inhibitor resistance positions. Six percent and 14% of patients had mutations at nucleoside reverse transcriptase inhibitor and/or nonnucleoside reverse transcriptase inhibitor resistance positions, respectively. Larger scale studies need to be undertaken to better define the genotypic variation of circulating Indian subtype C viruses and their potential impact on drug susceptibility and clinical outcome in treated individuals.
大多数关于HIV-1耐药性的研究都集中在B亚型病毒上;而在非B亚型占主导的发展中国家,相关数据较少。我们测定了印度南部未接受过抗逆转录病毒治疗的个体中,蛋白酶和逆转录酶耐药位点的突变发生率。从50名患者的血浆HIV-1 RNA中扩增出基因组的pol区。所有序列均聚类为HIV-1 C亚型。所有患者在已知的B亚型耐药位点至少有一个蛋白酶和/或逆转录酶突变。20%的患者在主要蛋白酶抑制剂耐药位点有突变,100%的患者在次要蛋白酶抑制剂耐药位点有突变。分别有6%和14%的患者在核苷类逆转录酶抑制剂和/或非核苷类逆转录酶抑制剂耐药位点有突变。需要开展更大规模的研究,以更好地界定印度流行的C亚型病毒的基因变异情况,以及它们对接受治疗个体的药物敏感性和临床结局的潜在影响。